OGE Energy Corp. posts a return on equity in line with industry peers, but a deeper dive reveals a reliance on debt that could signal heightened risk for investors in the evolving utilities sector.
Europe relies on China for the rare earth elements essential in transition technologies, but it's making a late bid to end dependency.
Deutsche Bank's 2025 net profit nearly doubled to €7.1bn, fueled by revenue gains and cost cuts across all divisions, even as German prosecutors launch a money-laundering investigation linked to the lender.
The Hotchkis & Wiley Large Cap Disciplined Value Fund identified financial technology leader Fiserv as a significant underperformer in its Q4 2025 letter, amid a broader market rally driven by tech. The fund's critique comes as Fiserv shares have shed over 70% of their value in the past year.
General Motors' stock climbed after the company raised its annual outlook, becoming a standout performer in Hotchkis & Wiley's value fund during a quarter marked by investor wariness over concentrated market gains.
The Eurozone economy expanded by 1.5% in 2025, outpacing forecasts despite ongoing trade tensions with the US, as a recovery in Germany and robust growth in Spain helped offset a slowdown in France.
Hotchkis & Wiley's value fund outperformed benchmarks in 2025, with FedEx highlighted as a key contributor. The logistics giant's shares rose over 20% in the past year, buoyed by strong domestic package performance, even as the fund remains selective in a top-heavy market.
With consumer staples out of favor and a yield surpassing the S&P 500, Coca-Cola's resilient business and decades of dividend growth present a compelling case for long-term investors.
Amid a broader market rally, Warner Bros. Discovery's stock surged over 164% in the past year, driven by reported takeover interest. The Hotchkis & Wiley Large Cap Disciplined Value Fund highlighted the media giant as a key contributor in its latest investor letter, pointing to its attractive valuation in a frothy market.
As Nvidia's historic rally sets a high bar, investors are looking for the next wave of AI winners. Micron Technology and Amazon present compelling cases with unique drivers in the booming ecosystem.
CNBC's Jim Cramer highlights Texas Instruments (TXN) for its operational strength, as the chipmaker navigates a challenging market with better-than-expected guidance and analyst optimism.
As Nike shares face pressure, CNBC's Jim Cramer points to the company's ongoing turnaround and potential in the Chinese market as key catalysts for recovery, despite recent analyst downgrades.
CNBC's Jim Cramer offers a detailed take on NVIDIA's stock trajectory, highlighting analyst optimism around its data center partnerships while expressing skepticism over reported Chinese AI chip purchases.
CNBC's Jim Cramer refrained from declaring a floor for Broadcom's stock amid mixed analyst sentiment and growing competition in the crucial AI semiconductor sector.
CNBC's Jim Cramer highlights Micron Technology as a key beneficiary of the AI boom and ongoing memory chip shortages, with shares soaring nearly 400% in a year on robust data center demand.
As industry analysts warn of a critical NAND wafer shortage in 2026-2027, SanDisk's stock soars. Jim Cramer highlights the memory maker's positioning, with Mizuho and Benchmark raising price targets significantly on expectations of a 330% price spike.
Damascus residents face electricity bills exceeding their monthly incomes after a massive government price hike, sparking rare public protests and deepening the crisis for a war-weary population.
Carnival Corporation's shares have surged over three years, yet a detailed financial analysis suggests the cruise giant may still be trading at a significant discount. As the industry navigates post-pandemic recovery and debt reduction, investors are weighing if the current price reflects underlying value or lingering risks.
Intel's contract chipmaking division is reportedly in advanced discussions with tech giants Nvidia and Apple to manufacture key components starting in 2028, a potential game-changer for the semiconductor industry's supply chain.
Shares of antibody discovery firm AbCellera Biologics (ABCL) present a complex picture for investors, with strong one-year gains overshadowed by steep declines over longer horizons. As the stock trades near $3.86, a significant gap emerges between its market price and some analyst fair value estimates, raising questions about its premium valuation in a challenging biotech market.
